Paradromics,

Paradromics is a neurotechnology company founded in 2015, focused on developing high-bandwidth brain-computer interfaces (BCIs) to help individuals with severe brain health conditions, particularly those with motor impairments. Their flagship product, the Connexus BCI, features over 1,600 independent recording channels, allowing for advanced neural recording and the conversion of brain activity into speech or control of digital devices. The company has achieved significant milestones, including securing contracts with NIH and DARPA, relocating its headquarters to Austin, Texas, and receiving multiple FDA Breakthrough Device Designations. Paradromics has a multidisciplinary team of over 60 experts and has raised more than $105 million in venture funding. They are actively working towards commercialization of their technology, with clinical trials underway to evaluate the safety and functionality of the Connexus BCI for speech restoration.